InvestorsHub Logo
Followers 203
Posts 23582
Boards Moderated 0
Alias Born 12/23/2012

Re: None

Thursday, 12/16/2021 1:58:44 PM

Thursday, December 16, 2021 1:58:44 PM

Post# of 802
BioNTech is more than a COVID-19 vaccine company - Morgan Stanley
Dec. 16, 2021 12:58 PMBioNTech SE (BNTX)By: Dulan Lokuwithana, SA News Editor
BioNTech And Pfizer To Begin Clinical Trial For Covid-19 Vaccine
Thomas Lohnes/Getty Images News

While COVID-related revenue will remain as its key valuation driver, next year, investors of BioNTech (NASDAQ:BNTX) will start to see the company’s non-COVID pipeline, the analysts at Morgan Stanley argue, initiating its coverage on the stock with an Equal Weight rating.

“BioNTech is more than a COVID-19 mRNA company,” they added, citing its diverse pipeline targeted at oncology and infectious diseases including influenza, melanoma, and head/neck cancer.

As key drivers for its stock, the analysts led by Matthew Harrison term the impact of new variants, requirements for annual boosters, and the company’s efforts to compete with a pan respiratory vaccine. They also highlight a range of readouts scheduled for next year in its oncology pipeline.

However, comparing its market cap to those of Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and Vertex (NASDAQ:VRTX), the team also argues that the German biotech appears fairly valued despite having a single product with an uncertain long-term outlook. The price target of $294 per share implies a premium of ~2.4% to the last close.

As shown in the diagram below, the Bullish recommendations on BioNTech (BNTX) have gradually increased on Wall Street over the past six months.


BNTX $$$$

DO always your own DD , before you invest in any stock !

My opinion is always only my opinion !

Good Luck to all !

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BNTX News